
# Title 42— THE PUBLIC HEALTH AND WELFARE
### CHAPTER 7— SOCIAL SECURITY
#### § 1395w–114b. Manufacturer rebate for certain drugs with prices increasing faster than inflation
##### (g) Definitions

In this section:

(1) Part D rebatable drug

(A) In general

Except as provided in subparagraph (B), the term “part D rebatable drug” means, with respect to an applicable period, a drug or biological described in subparagraph (C) that is a covered part D drug (as such term is defined under section 1395w–102(e) of this title ).

(B) Exclusion

(i) In general

Such term shall, with respect to an applicable period, not include a drug or biological if the average annual total cost under this part for such period per individual who uses such a drug or biological, as determined by the Secretary, is less than, subject to clause (ii), $100, as determined by the Secretary using the most recent data available or, if data is not available, as estimated by the Secretary.

(ii) Increase

The dollar amount applied under clause (i)

(I) for the applicable period beginning October 1, 2023 , shall be the dollar amount specified under such clause for the applicable period beginning October 1, 2022 , increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with October of 2023; and

(II) for a subsequent applicable period, shall be the dollar amount specified in this clause for the previous applicable period, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with October of the previous period.  Any dollar amount specified under this clause that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

(C) Drug or biological described

A drug or biological described in this subparagraph is a drug or biological that, as of the first day of the applicable period involved, is

(i) a drug approved under a new drug application under section 355(c) of title 21 ;

(ii) a drug approved under an abbreviated new drug application under section 355(j) of title 21 , in the case where

(I) the reference listed drug approved under section 355(c) of title 21 , including any “authorized generic drug” (as that term is defined in section 355(t)(3) of title 21 ), is not being marketed, as identified in the Food and Drug Administration’s National Drug Code Directory;

(II) there is no other drug approved under section 355(j) of title 21 that is rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of “Approved Drug Products with Therapeutic Equivalence Evaluations”) and that is being marketed, as identified in the Food and Drug Administration’s National Drug Code Directory;

(III) the manufacturer is not a “first applicant” during the “180-day exclusivity period”, as those terms are defined in section 355(j)(5)(B)(iv) of title 21 ; and

(IV) the manufacturer is not a “first approved applicant” for a competitive generic therapy, as that term is defined in section 355(j)(5)(B)(v) of title 21 ; or

(iii) a biological licensed under section 262 of this title .

(2) Unit

The term “unit” means, with respect to a part D rebatable drug, the lowest dispensable amount (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, as reported under section 1396r–8 of this title .

(3) Payment amount benchmark period

The term “payment amount benchmark period” means the period beginning January 1, 2021 , and ending in the month immediately prior to October 1, 2021 .

(4) Benchmark period CPI–U

The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January 2021.

(5) Applicable period CPI–U

The term “applicable period CPI–U” means, with respect to an applicable period, the consumer price index for all urban consumers (United States city average) for the first month of such applicable period.

(6) Average manufacturer price

The term “average manufacturer price” has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1396r–8(k)(1) of this title , with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1396r–8 of this title .

(7) Applicable period

The term “applicable period” means a 12-month period beginning with October 1 of a year (beginning with October 1, 2022 ).
